HARJEET CHEEMA: Open Payments
NPI 1629726815 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,849 in 53 payments from 10 companies in 2025. Trend: 2023 $1,823 · 2024 $1,736 · 2025 $1,849
Food & beverage: $1,849
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $338 |
| E.R. Squibb & Sons, L.L.C. | 7 | $335 |
| Alkermes, Inc. | 5 | $290 |
| Neurocrine BioSciences, Inc. | 4 | $285 |
| Otsuka America Pharmaceutical, Inc. | 5 | $188 |
| Janssen Pharmaceuticals, Inc | 7 | $186 |
| Vanda Pharmaceuticals Inc. | 8 | $141 |
| Lundbeck LLC | 2 | $52 |
| ABBVIE INC. | 1 | $19 |
| Novo Nordisk Inc | 1 | $16 |
Products named: CAPLYTA, COBENFY, INGREZZA, LYBALVI, INVEGA SUSTENNA, FANAPT, ABILIFY MAINTENA, REXULTI.
Industry payments across CA — which companies pay providers there.
